NTRA vs. SRPT
NTRA (Natera, Inc.) and SRPT (Sarepta Therapeutics, Inc.) are both stocks. Both are in the Healthcare sector — NTRA in Diagnostics & Research, SRPT in Biotechnology. Over the past 10 years, NTRA returned 33.19%/yr vs 0.43%/yr for SRPT. At a 0.32 correlation, their price movements are largely independent.
Performance
NTRA vs. SRPT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NTRA achieves a -7.14% return, which is significantly higher than SRPT's -24.49% return. Over the past 10 years, NTRA has outperformed SRPT with an annualized return of 33.19%, while SRPT has yielded a comparatively lower 0.43% annualized return.
NTRA
- 1D
- -2.78%
- 1M
- 2.63%
- YTD
- -7.14%
- 6M
- -10.10%
- 1Y
- 32.39%
- 3Y*
- 63.35%
- 5Y*
- 17.58%
- 10Y*
- 33.19%
SRPT
- 1D
- -7.72%
- 1M
- -24.38%
- YTD
- -24.49%
- 6M
- -20.62%
- 1Y
- -56.94%
- 3Y*
- -49.36%
- 5Y*
- -26.11%
- 10Y*
- 0.43%
NTRA vs. SRPT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NTRA Natera, Inc. | -7.14% | 44.72% | 152.71% | 55.94% | -56.99% | -6.16% | 195.40% | 141.33% | 55.28% | -23.23% |
SRPT Sarepta Therapeutics, Inc. | -24.49% | -82.30% | 26.09% | -25.58% | 43.90% | -47.18% | 32.12% | 18.24% | 96.14% | 102.84% |
Correlation
The correlation between NTRA and SRPT is 0.32, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.32 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.30 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.36 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.33 |
Correlation (All Time) Calculated using the full available price history since Jul 6, 2015 | 0.32 |
Fundamentals
NTRA:
$30.10B
SRPT:
$1.98B
NTRA:
-$1.64
SRPT:
$0.60
NTRA:
11.73
SRPT:
0.81
NTRA:
16.97
SRPT:
1.32
NTRA:
$2.50B
SRPT:
$2.18B
NTRA:
$1.63B
SRPT:
$751.34M
NTRA:
-$294.86M
SRPT:
$107.91M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NTRA vs. SRPT — Risk / Return Rank
NTRA
SRPT
NTRA vs. SRPT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Natera, Inc. (NTRA) and Sarepta Therapeutics, Inc. (SRPT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| NTRA | SRPT | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.77 | -0.55 | +1.32 |
Sortino ratioReturn per unit of downside risk | 1.24 | -0.32 | +1.56 |
Omega ratioGain probability vs. loss probability | 1.16 | 0.95 | +0.21 |
Calmar ratioReturn relative to maximum drawdown | 1.24 | -0.79 | +2.02 |
Martin ratioReturn relative to average drawdown | 2.65 | -1.05 | +3.71 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| NTRA | SRPT | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.77 | -0.55 | +1.32 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.31 | -0.38 | +0.69 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.55 | 0.01 | +0.54 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.37 | -0.03 | +0.40 |
Drawdowns
NTRA vs. SRPT - Drawdown Comparison
The maximum NTRA drawdown since its inception was -77.74%, smaller than the maximum SRPT drawdown of -98.17%. Use the drawdown chart below to compare losses from any high point for NTRA and SRPT.
Loading charts...
Drawdown Indicators
| NTRA | SRPT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -77.74% | -98.17% | +20.43% |
Max Drawdown (1Y)Largest decline over 1 year | -28.20% | -72.26% | +44.06% |
Max Drawdown (3Y)Largest decline over 3 years | -39.94% | -92.72% | +52.78% |
Max Drawdown (5Y)Largest decline over 5 years | -77.74% | -92.72% | +14.98% |
Max Drawdown (10Y)Largest decline over 10 years | -77.74% | -93.33% | +15.59% |
Current DrawdownCurrent decline from peak | -16.38% | -90.91% | +74.53% |
Average DrawdownAverage peak-to-trough decline | -33.50% | -68.14% | +34.64% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.15% | 53.85% | -40.70% |
Volatility
NTRA vs. SRPT - Volatility Comparison
Natera, Inc. (NTRA) has a higher volatility of 18.89% compared to Sarepta Therapeutics, Inc. (SRPT) at 17.44%. This indicates that NTRA's price experiences larger fluctuations and is considered to be riskier than SRPT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NTRA | SRPT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 18.89% | 17.44% | +1.45% |
Volatility (6M)Calculated over the trailing 6-month period | 34.39% | 53.16% | -18.77% |
Volatility (1Y)Calculated over the trailing 1-year period | 42.39% | 103.50% | -61.11% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 57.01% | 69.82% | -12.81% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 60.94% | 70.76% | -9.82% |
Dividends
NTRA vs. SRPT - Dividend Comparison
Neither NTRA nor SRPT has paid dividends to shareholders.
Financials
NTRA vs. SRPT - Financials Comparison
This section allows you to compare key financial metrics between Natera, Inc. and Sarepta Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NTRA vs. SRPT - Profitability Comparison
NTRA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Natera, Inc. reported a gross profit of 451.44M and revenue of 696.64M. Therefore, the gross margin over that period was 64.8%.
SRPT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Sarepta Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 730.80M. Therefore, the gross margin over that period was 0.0%.
NTRA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Natera, Inc. reported an operating income of -93.52M and revenue of 696.64M, resulting in an operating margin of -13.4%.
SRPT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Sarepta Therapeutics, Inc. reported an operating income of 358.43M and revenue of 730.80M, resulting in an operating margin of 49.1%.
NTRA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Natera, Inc. reported a net income of -85.09M and revenue of 696.64M, resulting in a net margin of -12.2%.
SRPT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Sarepta Therapeutics, Inc. reported a net income of 330.96M and revenue of 730.80M, resulting in a net margin of 45.3%.
Frequently Asked Questions
NTRA and SRPT have a correlation of 0.32, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NTRA has higher volatility (18.89%) compared to SRPT (17.44%). In terms of maximum drawdown, NTRA dropped -77.74% vs SRPT's -98.17%.
NTRA currently has the higher Sharpe Ratio (0.77 vs -0.55), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NTRA and SRPT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer